Diabetes In Control This prospective study sought to identify the association between long-term sulfonylurea use and incident cardiovascular disease in type 2 diabetes patients who lacked cardiovascular disease at baseline using the Nurses' Health Study cohort. 4,902 ...
The Pharmaceutical Journal Joanna is a freelance medical writer with a BSc (Hons) in Medical Science & Pharmacology and 15 years' experience working in the field of medical communications. Journalistic work includes clinical research summaries, interviews, feature articles and ...
The Pharma Letter The Federal Joint Committee (G-BA) specified different appropriate comparator therapies for the sub-indications, resulting in a total of five comparisons: empagliflozin as monotherapy versus a sulfonylurea (A), in combination with metformin versus ...
The Pharmaceutical Journal Only 24.5% of patients on metformin needed a second glucose-lowering medication, compared with 37.1% given a sulfonylurea , 39.6% treated with a thiazolidinedione and 36.2% with a DPP-4 inhibitor. For the latter three drugs, metformin was the most ...
AJMC.com Managed Markets Network Study Design: Patients with T2DM who were treated with saxagliptin (N = 13,929), sulfonylurea (N = 117,756), or sitagliptin (N = 36,813) in 2010 or later were identified in a database of commercially insured beneficiaries. Patients were required to ...
PharmiWeb.com (press release) Hypoglycaemia has primarily been observed when Victoza® is combined with a sulfonylurea . Headquartered in Denmark, Novo Nordisk is a glob...
Medical Xpress The Federal Joint Committee (G-BA) specified different appropriate comparator therapies for the subindications, resulting in a total of five comparisons: empagliflozin as monotherapy versus a sulfonylurea (A), in combination with metformin versus ... and more »
Newswise (press release) Three of the medications being tested are sulfonylurea , DPP-4 inhibitor and GLP-1 agonist, all of which increase insulin levels either directly or indirectly. The fourth therapy is a long-acting insulin medication. If these medication combinations ... and more »
Farm and Ranch Guide San Diego - Cibus Global, a leader in non-transgenic trait development, and Rotam, a fast growing international company in the crop protection industry, have announced the launch of non-transgenic SU Canola™ ( Sulfonylurea Tolerant) in the United States.
News-Medical.net The Federal Joint Committee (G-BA) specified different appropriate comparator therapies for the subindications, resulting in a total of five comparisons...
